Changes in Beneficial Ownership · 4
ProKidney Corp.
PROKNASDAQEQUITYCurrent
Changes in Beneficial Ownership
Structured filing — 4
ownership.xml
Filing details
- Report period
- 2026-07-01
- Issuer
- PROKIDNEY CORP.
- Issuer CIK
- 0001850270
- Trading symbol
- PROK
Reporting owner 1
- Name
- Locke Kenneth Thomas
- Reporting owner CIK
- 0002139380
- Relationship
- Officer
- Officer title
- Chief Technical Officer
- Address
- 2000 FRONTIS PLAZA BLVD, SUITE 250, WINSTON-SALEM, NC, 27103
Derivative transactions
| Security | Conversion / exercise price (USD) | Transaction date | Code | Amount | A / D | Price (USD) | Exercisable | Expires | Underlying security | Underlying shares | Owned after | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee stock option (right to buy) | 1.89 | 2026-07-01 | A · Form 4 | 750,000 | A | 0 | [F1] | 2036-07-01 | Class A Common Stock | 750,000 | 750,000 | D |
Table key
- A · Form 4
- Acquisition by grant, award or otherwise under Rule 16b-3(d)
- A
- Acquired
- D
- Direct
Footnotes
- F1
- The option vests 25% on 1st anniversary of July 1, 2026 and the remaining 75% vests in substantially equal monthly installments for 36 months thereafter, subject to continued employment.↩ 1
Signature 1
- Signed
- /s/ Todd Girolamo, attorney in fact
- Date
- 2026-07-06
Company context
ProKidney, a pioneer in the treatment of CKD through innovations in cell therapy, was founded in 2015 after a decade of research. ProKidney’s lead product candidate, rilparencel (also known as REACT®), is a first-in-class, patented, proprietary autologous cell therapy with regenerative medicine advanced therapy designation that is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) study for its potential to preserve kidney function in patients with advanced CKD and type 2 diabetes. For more information, please visit www.prokidney.com.